COMPANY
Alcresta Therapeutics
Alcresta develops rare disease, enzyme-based products helping to address fat malabsorption (often due to exocrine pancreatic insufficiency) in patients who are enterally fed at home or in the hospital. We are developing a portfolio of point-of-care, enzyme-based products designed to improve nutritional care in a number of rare diseases. From company website Source · Oct 13, 2026
Timeline
- Trial start Not phased (device or behavioral study): Absorption and Safety With Sustained Use of RELiZORB Evaluation (ASSURE) Study source ↗
- Trial start Not phased (device or behavioral study): Safety, Tolerability and Fat Absorption Using Enteral Feeding In-line Enzyme Cartridge (Relizorb) source ↗
Clinical trials (lead sponsor) 2
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT02750501 | Absorption and Safety With Sustained Use of RELiZORB Evaluation (ASSURE) Study | Not phased (device or behavioral study) | Completed | Jul 20, 2016 | Mar 30, 2017 (actual) |
| NCT02598128 | Safety, Tolerability and Fat Absorption Using Enteral Feeding In-line Enzyme Cartridge (Relizorb) | Not phased (device or behavioral study) | Completed | 2015-11 | 2016-06 (actual) |